NASDAQ:GANX | Free Cash Flow | Gain Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2020-03-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$4.73M
2025-12-31-$4.62M
2025-03-31-$3.82M
2024-12-31-$3.45M
2024-03-31-$3.59M
2023-12-31-$5.66M
2023-03-31-$4.22M
2022-12-31-$3.9M
2022-03-31-$2.45M$7,825.00-$2.46M
2021-12-31-$4.15M$11,098.00-$4.16M
2021-03-31-$2.81M$28,488.00-$2.84M
2020-12-31-$1.31M$14,551.00-$1.32M
2020-03-31-$752,816.00$4,897.00-$757,713.00

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$18.47M
2024-12-31-$18.87M
2023-12-31-$18.87M
2022-12-31-$14.69M
2021-12-31-$12.37M$94,212.00-$12.46M
2020-12-31-$3.24M$20,826.00-$3.26M